Application of Radionuclides and Antibody -Drug Conjugates to Target Cancer
Keywords:
Targeted alpha therapy, Radionuclide therapy, Antibody-drug conjugates, Monoclonal antibody, Alpharadin®, Xofigo®, Bexxar®, Zevalin®, Adcetris®, KadcylaAbstract
Radionuclide therapy and antibody-drug conjugates are used to locate and kill cancer cells by the utilisation of monoclonal antibodies. These bio-vectors are able to transport a cytotoxic drug payload and/or radiation in the form of alpha or beta particles to bind onto antigen specific cancer cells initiating apoptosis. This inaugural article aims to deliver a brief account of these targeted therapies in the treatment of oncological disease states such as leukaemia, non-Hodgkin’s lymphoma, neuroendocrine tumours, breast cancer and prostate cancer bone metastases.
Downloads
Published
How to Cite
Issue
Section
License
All content published in Cancer Studies and Molecular Medicine (CSMM) is licensed under the Creative Commons Attribution 4.0 International License (CC BY 4.0). This license allows anyone to copy, distribute, transmit, and adapt the work — including for commercial purposes — provided appropriate credit is given to the original author(s) and source.
